Deutsche Bank
ALXN

Deutsche Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Deutsche Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,735
Closed -$383K – 5223
2017
Q3 		$383K Sell
2,735
-1,878
-41% -$255K ﹤0.01% 3553
2017
Q2 		$561K Buy
+4,613
New +$537K ﹤0.01% 3386

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Deutsche Bank's ALXN Position: Q3 2021 in Review

Deutsche Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,217,236 shares — an estimated $407M sold.

Deutsche Bank first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $407M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Deutsche Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Deutsche Bank sold 2,217,236 Alexion Pharmaceuticals shares in Q3 2021, an estimated $407M.
  • Deutsche Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Deutsche Bank's Alexion Pharmaceuticals position peaked at $407M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.